Identification of Early Markers for ALS

NCT ID: NCT07213440

Last Updated: 2025-10-08

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-09-30
• Study Completion Date: 2026-04-30

Brief Summary

Although several molecules have been proposed as biomarker candidates, a clinically established signature for an early or even premotor diagnosis of ALS is not available. Due to the already advanced, disease stage at the time of diagnosis as well as rapid disease progression, an early diagnosis is mandatory for efficacious disease-modifying therapies.

In this project, the investigators will develop a clinical molecular fingerprint of PGMC that will provide insight into the molecular pathogenesis of ALS and allow earlier diagnosis.

Conditions

Amyotrophic Lateral Sclerosis (ALS)

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

a single arm

all 3 patient groups will have the same tests

Group Type: OTHER

lumbar puncture

Intervention Type: PROCEDURE

After information and consent by the investigator, clinical data will be collected using a CRF and biological samples (Blood sampling, Urine sample, cephalo spinal fluid), lacrimal fluid sampling, and a smell test will be taken from all subjects at baseline and at 12 months.

Interventions

lumbar puncture

After information and consent by the investigator, clinical data will be collected using a CRF and biological samples (Blood sampling, Urine sample, cephalo spinal fluid), lacrimal fluid sampling, and a smell test will be taken from all subjects at baseline and at 12 months.

Intervention Type: PROCEDURE

Other Intervention Names

Blood sampling,Urine sample,survey,Lacrimal fluid sampling,Smell test

Eligibility Criteria

Inclusion Criteria

FIRST GROUP: Premotor gene mutation carriers (PGMC):

• 18-90 years of age
• Provision of a written informed consent
• Affiliation with a social security scheme or beneficiary of such a scheme
• Diagnosed by a clinically certified laboratory with a disease- causing mutation in a known ALS gene by predictive genetic testing
• No symptoms of motor neuron disease explainable otherwise than by mutation in a known ALS gene

SECOND GROUP: Control subjects to premotor gene mutation carriers (CTR):

• 18-90 years of age
• Provision of a written informed consent
• Affiliation with a social security scheme or beneficiary of such a scheme
• No known genetic mutation and no known ALS disease in close family
• No diagnosed motor-neuron disease

THIRD GROUP: ALS (EALS) / ALS mimics (MIM)

• 18-90 years of age
• provision of a written informed consent
• affiliation with a social security scheme or beneficiary of such a scheme
• Patients with pure motor symptom or early ALS (EALS) or ALS mimics (MIM)

EALS are patients with pure motor symptom / early motor symptoms of ALS, including those, where the diagnosis of ALS can already be made. These may be patients who meet the following criteria:

According to El Escorial criteria : patients who can be classified as possible ALS or those who show upper motor neuron (UMN) signs only or lower motor neuron (LMN) signs only, so that classification as possible ALS is also not possible. Symptoms should not persist for more than 12 months.

According to Gold Coast criteria: Patients who do not fulfill the criterion of temporal progression or patients who only show UMN signs or only LMN signs in one region and thus do not fulfill the diagnostic criteria of ALS.

Exclusion Criteria

• Inability to express consent to the study
• Persons subject to a judicial safeguard measure, under guardianship or curatorship.
• Linguistic incapacity or psychic refusal to read the information.
• Pregnant women
• Foreseen inability to attend scheduled visits
• Persons refusing to take one of the following samples: Acquisition of blood samples, Acquisition of tear fluid samples, Acquisition of urine sample

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 90 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Technical University of Munich

OTHER

Sponsor Role: collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

CHU Tours

Tours, France, France

Site Status: RECRUITING

Countries

France

Central Contacts

Philippe CORCIA, Professor

Role: CONTACT

philippe.corcia@univ-tours.fr

+33247473724 ext. +33247473724

Facility Contacts

Philippe Corcia, Pr

Role: primary

philippe.corcia@univ-tours.fr

Other Identifiers

IDRCB

Identifier Type: REGISTRY

Identifier Source: secondary_id

C23-41

Identifier Type: -

Identifier Source: org_study_id